Feelings are running high in the UK pharmaceutical industry at the moment, with fears about a new NHS drugs budget squeeze and Brexit causing major concerns.
New rules on market access introduced by NICE from 1 April will affect most new medicines – but gaining access to ultra-orphan drugs could become much more difficult.
Pharma and patient groups are dismayed by new cost-capping and delaying measures, which they say will further restrict access to new medicines in England.
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough